Logos Global Management’s Celldex Therapeutics CLDX Stock Holding History

Logos Global Management’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$14.3M	Buy	450,000 +100,000	+29%	+$2.73M	0.71%	41
2025 Q4	$9.51M	Buy	+350,000	New	+$9.22M	0.57%	43
2025 Q3	–	Sell	-600,000	Closed	-$12.2M	–	63
2025 Q2	$12.2M	Buy	+600,000	New	+$11.7M	1.35%	25
2024 Q4	–	Sell	-900,000	Closed	-$30.6M	–	53
2024 Q3	$30.6M	Buy	+900,000	New	+$34.3M	3.3%	9
2024 Q2	–	Sell	-650,000	Closed	-$27.3M	–	62
2024 Q1	$27.3M	Buy	+650,000	New	+$26.7M	2.21%	15
2020 Q4	–	Sell	-1,200,000	Closed	-$17.8M	–	60
2020 Q3	$17.8M	Sell	1,200,000 -800,000	-40%	-$9.37M	2.28%	13
2020 Q2	$26M	Buy	+2,000,000	New	+$8.86M	5.2%	3

Other funds holding CLDX

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Logos Global Management's CLDX Position: Q1 2026 in Review

Logos Global Management increased its Celldex Therapeutics (CLDX) stake by 29% in Q1 2026, buying an estimated $2.73M and bringing the position to 450,000 shares worth $14.3M. The position accounts for 0.71% of the portfolio, ranked #41.

Logos Global Management first reported a position in CLDX in Q2 2020 and has held it in 7 quarters since. The position peaked at $30.6M in Q3 2024. 228 funds tracked by Wall St. Rank hold CLDX as of Q1 2026.

Logos Global Management held 450,000 shares of Celldex Therapeutics worth $14.3M as of Q1 2026.
Logos Global Management bought 100,000 Celldex Therapeutics shares in Q1 2026, an estimated $2.73M.
Celldex Therapeutics made up 0.71% of Logos Global Management's portfolio in Q1 2026, its #41 holding.
Logos Global Management first reported a position in Celldex Therapeutics in Q2 2020 and has held it in 7 quarters since.
Logos Global Management's Celldex Therapeutics position peaked at $30.6M in Q3 2024.
228 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2026.

Based on Logos Global Management's 13F filing for Q1 2026, filed 15 May 2026.